Wallclav 625 LB Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 million spores. Amoxycillin, a broad-spectrum penicillin antibiotic, acts by inhibiting bacterial cell wall synthesis, effectively targeting a wide range of gram-positive and gram-negative bacteria. Clavulanic Acid serves as a beta-lactamase inhibitor, preventing enzymatic degradation of amoxycillin and thereby enhancing its antibacterial efficacy against beta-lactamase producing resistant strains. The inclusion of Lactobacillus spores aids in maintaining and restoring normal gut flora, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances commonly observed during antibiotic therapy. Wallclav 625 LB is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media. It is particularly useful in infections caused by beta-lactamase producing organisms. The tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection and patient-specific factors such as renal function. Caution is advised in patients with a history of penicillin allergy or hypersensitivity. Adverse effects may include gastrointestinal upset, hypersensitivity reactions, and rarely, hepatic dysfunction.